TRE in Type 2 Diabetes (See Food Study 3) (SFS3)
TRE in Type 2 Diabetes Mellitus (See Food Study 3)
Sponsor: University of Minnesota
A observational or N/A phase clinical study on Type2Diabetes, this trial is completed. The trial is conducted by University of Minnesota and has accumulated 13 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Apr 16, 2026 — Present [daily]
Completed
Status: Active Not Recruiting → Completed · Phase: NA → None
-
Feb 2026 — Apr 2026 [monthly]
Active Not Recruiting NA
-
Jan 2026 — Feb 2026 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Apr 2025 — Jan 2026 [monthly]
Recruiting NA
-
Sep 2024 — Apr 2025 [monthly]
Recruiting NA
▶ Show 8 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
May 2024 — Jul 2024 [monthly]
Recruiting NA
-
Jun 2023 — May 2024 [monthly]
Recruiting NA
-
Mar 2023 — Jun 2023 [monthly]
Recruiting NA
-
Dec 2022 — Mar 2023 [monthly]
Recruiting NA
-
Jul 2022 — Dec 2022 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
May 2022 — Jul 2022 [monthly]
Not Yet Recruiting NA
-
Apr 2022 — May 2022 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
Hyperglycemia in patients with Type 2 Diabetes Mellitus is initially treated with metformin coupled with intentional caloric restriction, which is difficult to sustain due to multiple barriers, including acquiring the necessary knowledge, teaching the intervention, cost of delivery and potential burden on quality of life. In contrast to intentionally restricting calories, time restricted eating (TRE), presents a simplified view of eating focused on restricting the eating window, which allows ad libitum intake per a person's dietary preferences during a daily fixed eating window. This study proposes a 24 week feasibility study to test if TRE is a viable alternative to Caloric Restriction in improving glycemic measures while accounting for weight loss in overweight/obese patients \[BMI:25-45 kg/m2\] with metformin-only treated Type 2 diabetes.
Contact Information
- University of Minnesota
For direct contact, visit the study record on ClinicalTrials.gov .